SMS Lifesciences India Limited has informed regarding USFDA Inspection.
HALEOSLABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
SMS Lifesciences India Limited informed the exchanges that the US Food and Drug Administration (USFDA) completed an inspection at its API manufacturing facility located in Kazipally, Telangana (Unit-1) from May 5 to May 9, 2025. The inspection concluded with one observation in Form 483, which the company clarified is purely procedural in nature and does not relate to data integrity or product quality. The company stated there is no impact on its financial position, operations, or other activities due to this observation. The final Establishment Inspection Report (EIR) is awaited after SMS Lifesciences submits its formal response to the USFDA.
This is a positive/neutral outcome for shareholders — a single procedural observation with no impact on data integrity, product quality, or operations signals strong compliance, which is supportive of the company's US market prospects. No immediate negative effect on the stock is expected.